SB-649868

SB-649868
Clinical data
ATC code	None;
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name N-([(2S)-1-([5-(4-fluorophenyl)-2-methyl-4-thiazolyl]carbonyl)-2-piperidinyl]methyl)-4-benzofurancarboxamide;
PubChem CID	25195495;
ChemSpider	25069706;
ChEMBL	ChEMBL1272307;
CompTox Dashboard (EPA)	DTXSID90191491 ;
Chemical and physical data
Formula	C26H24FN3O3S
Molar mass	477.549 g/mol (free base) g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=NC(=C(S1)C2=CC=C(C=C2)F)C(=O)N3CCCC[C@H]3CNC(=O)C4=C5C=COC5=CC=C4;
	InChI InChI=1S/C26H24FN3O3S/c1-16-29-23(24(34-16)17-8-10-18(27)11-9-17)26(32)30-13-3-2-5-19(30)15-28-25(31)21-6-4-7-22-20(21)12-14-33-22/h4,6-12,14,19H,2-3,5,13,15H2,1H3,(H,28,31)/t19-/m0/s1; Key:ZJXIUGNEAIHSBI-IBGZPJMESA-N;

SB-649868 is a dual orexin receptor antagonist in development by GlaxoSmithKline.[1] The drug is currently in phase II development for insomnia.

A phase I study evaluated doses up to 80 mg, resulting in significant improvement in sleep latency without adverse effects.[2]

In randomized, double-blind, placebo-controlled crossover trials, the 10 and 30 mg doses increased sleep time and reduced sleep latency.[3] The subsequent study added a 60 mg dose and observed dose-dependent sleep promotion.[4]

References

Renzulli C, Nash M, Wright M, Thomas S, Zamuner S, Pellegatti M, et al. (February 2011). "Disposition and metabolism of [14C]SB-649868, an orexin 1 and 2 receptor antagonist, in humans". Drug Metabolism and Disposition. 39 (2): 215–27. doi:10.1124/dmd.110.035386. PMID 21045199. S2CID 1995624.
Bettica P, Nucci G, Pyke C, Squassante L, Zamuner S, Ratti E, et al. (August 2012). "Phase I studies on the safety, tolerability, pharmacokinetics and pharmacodynamics of SB-649868, a novel dual orexin receptor antagonist". Journal of Psychopharmacology. 26 (8): 1058–70. doi:10.1177/0269881111408954. PMID 21730017. S2CID 29578953.
Bettica P, Squassante L, Groeger JA, Gennery B, Winsky-Sommerer R, Dijk DJ (April 2012). "Differential effects of a dual orexin receptor antagonist (SB-649868) and zolpidem on sleep initiation and consolidation, SWS, REM sleep, and EEG power spectra in a model of situational insomnia". Neuropsychopharmacology. 37 (5): 1224–33. doi:10.1038/npp.2011.310. PMC 3306884. PMID 22237311.
Bettica P, Squassante L, Zamuner S, Nucci G, Danker-Hopfe H, Ratti E (August 2012). "The orexin antagonist SB-649868 promotes and maintains sleep in men with primary insomnia". Sleep. 35 (8): 1097–104. doi:10.5665/sleep.1996. PMC 3397789. PMID 22851805.

SB-649868

See also

References

Further reading